banner
 
bar

program

slides
bar
 
 

New Frontiers and Clinical Advances in Immunotherapy for Asthma

WebCAST

CME Test
After Viewing Program, Please Click Here to Access the CME Test
Viewer Survey
How long did you spend on this program?

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

2.0 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in managing patients with asthma.

Release Date

September 26, 2016

Expiration Date

September 26, 2018

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period September 26, 2016 through September 26, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 6 segments totaling 2.0 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.

Registration

Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Commercial Support

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. Complete Conference Management is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Sally Wenzel, MD
Program Co-Chair
Professor of Medicine
Division of Pulmonary, Allergy, and Critical Care Medicine
Director, Asthma Institute
University of Pittsburgh
Pittsburgh, PA

Consultant: AstraZeneca, Novartis, Sanofi-unpaid, Regeneron – unpaid
Grant/Research Support: Sanofi, GSK, AstraZeneca, Novartis, Genentech



Rohit Katial, MD
Associate Vice President for Clinical Research and Industry Relationships
Co-Director, Asthma Institute
Director, Allergy and Clinical Immunology Fellowship
Professor, Helen Wohlberg & Herman Lambert Chair in Pharmacokinetics
Division of Allergy and Clinical Immunology, Department of Medicine
National Jewish Health
Denver, CO

Consultant: Teva, Meda, AstraZeneca
Speaker’s Bureau: Meda



Michael E. Wechsler, MD
Program Co-Chair
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Co-Director, The Cohen Family Asthma Institute
National Jewish Health
Denver, CO

Consultant: AstraZeneca, Teva, Mylan, Genentech, Novartis, Sanofi, Regeneron, Boston Scientific, Vectura, Theravance
Grant/Research Support: Sanofi



Chris E. Brightling, MD
NIHR Senior Investigator and Clinical Professor in Respiratory Medicine
Department of Respiratory Medicine
Institute for Lung Health
Leicester-Warwick Medical School
University Hospitals of Leicester
Leicester, UK

Consultant: GSK, MedImmune/AZ, Chiesi, BI, Novartis, Theravance, Vectura, Roche/Genentech
Grant/Research Support: GSK, MedImmune/AZ, Chiesi, BI, Novartis, Theravance, Vectura, Roche/Genentech, Pfizer, Mologics

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Manage patients with moderate-to-severe asthma, especially those who have failed maintenance therapy with ICS and LABAs;
  • Apply national and international professional association-based guidelines for assessment, risk stratification, and sequential management of patients with moderate and severe asthma with refractory characteristics;
  • Explain that asthma is a chronic disease with underlying pathoimmunological underpinnings that can be segregated, to some degree, into genetic and phenotypic subtypes based on clinical markers;
  • Outline existing treatments for asthma, and explain why and in whom these non-biologic therapies frequently produce suboptimal clinical responses;
  • Describe evolving immunologic approaches targeting the Th2 pathway inhibition, and specifically IL-4 and IL-13 cytokines, and the mechanism(s) of action for therapies directed at these targets and the rationale for their efficacy in patients with asthma;

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.

Disclaimer

Copyright © 2016 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.


bar

program

slides
bar

I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC

 
6

 

Key Program Topics Include:

Alefacept
AN2728
anti-IL-4Rα
atopic dermatitis
Azathioprine
Azathioprine
cream in Phase 2

(AstraZeneca)
Cyclosporine
Dupilumab
Efalizumab
effects on the epidermis in AD
IL-17
Imuran

 

JAK inhibitor
Methotrexate
MTX
Mycophenolate mofetil
Mycophenolate Mofetil
NBUVB
PDE4 inhibitors
Probiotics

roflumilast
Th2 Cytokine
Tofacitinib
urticaria
Vitamin D